Shacham Sharon 4
4 · Karyopharm Therapeutics Inc. · Filed Mar 1, 2021
Insider Transaction Report
Form 4
Shacham Sharon
CSO & Pres. Res. & Dev.
Transactions
- Award
Stock Option (right to buy)
2021-02-25+153,500→ 153,500 totalExercise: $14.56Exp: 2031-02-24→ Common Stock (153,500 underlying) - Award
Common Stock
2021-02-25+57,200→ 718,826 total(indirect: By Spouse) - Award
Common Stock
2021-02-25+57,200→ 920,152 total - Award
Stock Option (right to buy)
2021-02-25+153,500→ 153,500 total(indirect: By Spouse)Exercise: $14.56Exp: 2031-02-24→ Common Stock (153,500 underlying)
Footnotes (4)
- [F1]Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 25, 2022.
- [F2]The reporting person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 57,200 newly awarded RSUs, 86,500 RSUs previously reported in Table II, and 776,452 shares of common stock.
- [F3]The spouse of the reporting person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 57,200 newly awarded RSUs, 86,500 RSUs previously reported in Table II, and 575,126 shares of common stock.
- [F4]This option was granted on February 25, 2021 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 25, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter.